Waldenström Macroglobulinemia: Nutrition and Lifestyle Support

Waldenström macroglobulinemia (WM) is an indolent lymphoplasmacytic lymphoma with IgM paraprotein. Nutrition supports treatment tolerance and quality of life—not a cure.

Nutritional Priorities

1. Protein Adequacy: 1.2–1.5 g/kg/day (lean poultry, fish, eggs, legumes, Greek yogurt) — counters catabolism, supports immunoglobulin synthesis (paradoxical but needed for host defense).
2. Anti-Inflammatory Pattern: Mediterranean diet — polyphenols (berries, olive oil, nuts, greens), omega-3 (fatty fish, walnuts, flax), fiber (whole grains, legumes). Reduces NF-κB signaling.
3. Hyperviscosity Awareness: IgM >4–5 g/dL → symptomatic hyperviscosity. Hydration critical (2.5–3 L/day); avoid volume depletion. Plasmapheresis for acute syndrome.
4. Neuropathy Support: B12, B6, folate, alpha-lipoic acid, acetyl-L-carnitine — discuss with team (B6 excess worsens neuropathy).
5. Bone Health: Vitamin D 2000–4000 IU, calcium 1000–1200 mg, weight-bearing exercise — WM + rituximab + age ↑ fracture risk.
6. Anemia Management: Iron-rich foods (heme + non-heme + vitamin C) if iron-deficient; but most WM anemia is anemia of chronic disease — ESA/transfusion per guidelines.

Lifestyle Factors

• Alcohol: Minimize (liver metabolism, neuropathy, IgM interaction).
• Exercise: 150 min moderate aerobic + resistance 2×/wk — reduces fatigue, improves neuropathy, maintains muscle.
• Infection Prevention: Vaccines current (non-live); hygiene; prompt eval for fever (neutropenia risk on therapy).
• Stress/Sleep: CBT-I, mindfulness — fatigue is dominant symptom.

Supplements: Caution Required

• Green tea/EGCG: Theoretical benefit; case reports of hepatotoxicity with high-dose extract.
• Curcumin: Poor bioavailability; drug interactions (CYP).
• Cannabis/CBD: No WM data; CYP3A4 interaction with BTKi/venetoclax.
• Always disclose to oncologist.

Team Approach

Oncologist + dietitian (oncology-certified) + PT + palliative care. Nutrition is adjunctive—BTKi (ibrutinib/zanubrutinib), anti-CD20, proteasome inhibitors, venetoclax, clinical trials are disease-modifying.